Energenesis Biomedical Co

Energenesis Biomedical Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Energenesis Biomedical Co (6657.TW) as of Nov 4, 2026 is -275.28 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -255.17 M TWD — a change of 7.88% (lower).

EBITDA

-275.28 MTWD

YoY

7.88%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Energenesis Biomedical Co is 2025 -275.28 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Energenesis Biomedical Co was 2024 -255.17 M TWD. It decreases by 7.88% lower compared to the previous year.

The Energenesis Biomedical Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-108.66 M TWD
Jan 1, 2019
-149.20 M TWD
Jan 1, 2020
-129.13 M TWD
Jan 1, 2021
-119.95 M TWD
Jan 1, 2022
-265.46 M TWD
Jan 1, 2023
-261.84 M TWD
Jan 1, 2024
-255.17 M TWD
Jan 1, 2025
-275.28 M TWD
The Energenesis Biomedical Co EBITDA history
YEAREBITDAYoY
-275.28 MTWD+7.88%
-255.17 MTWD-2.55%
-261.84 MTWD-1.36%
-265.46 MTWD+121.30%
-119.95 MTWD-7.11%
-129.13 MTWD-13.45%
-149.20 MTWD+37.30%
-108.66 MTWD+48.97%
-72.94 MTWD+103.86%
-35.78 MTWD+133.86%
-15.30 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Energenesis Biomedical Co Stock analysis

What does Energenesis Biomedical Co do? Energenesis Biomedical Co., Ltd. develops new drugs, focusing on experimental service analysis and reagent sales as its main products. The company's primary new drugs include ENERGI-F703 for diabetic foot ulcers, ENERGI-F701 for abnormal alopecia, ENERGI-F711 for burns, and ENERGI-F706 for cachexia. These products target medical professionals and healthcare institutions seeking innovative treatments for specific conditions. The firm generates revenue through the sale of experimental services and reagents, as well as the commercialization of its drug pipeline. Energenesis Biomedical's product portfolio is centered around four key drug candidates, each addressing distinct medical needs. ENERGI-F703 addresses diabetic foot ulcers, a common complication in diabetes management, while ENERGI-F701 targets abnormal alopecia, a condition affecting hair growth. ENERGI-F711 is designed for burn treatment, and ENERGI-F706 focuses on cachexia, a wasting syndrome often associated with chronic diseases. These drugs are developed for direct sales to healthcare providers and institutions. The company's revenue streams are derived from two main areas: the sale of experimental service analysis and reagent products, alongside the future commercialization of its drug candidates. Healthcare institutions and medical professionals are the primary buyers of these products, seeking advanced solutions for diabetic foot ulcers, alopecia, burns, and cachexia. Energenesis Biomedical's business model relies on the successful development and market entry of its drug pipeline to generate sustained revenue. Energenesis Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Energenesis Biomedical Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Energenesis Biomedical Co is -275.28 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Energenesis Biomedical Co changed from -255.17 M TWD to -275.28 M TWD, representing a 7.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Energenesis Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Energenesis Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Energenesis Biomedical Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Energenesis Biomedical Co